Literature DB >> 15935883

IL-6 produced by type I IFN DC controls IFN-gamma production by regulating the suppressive effect of CD4+ CD25+ regulatory T cells.

Olivier Detournay1, Naima Mazouz, Michel Goldman, Michel Toungouz.   

Abstract

The dendritic cell family is composed of different subsets differentially governing the immune response. Type I interferon (IFN) dendritic cells (DC) are endowed with the ability to trigger both Th1 and Th2 type responses. In view of the pivotal role of regulatory T cells in limiting the effectiveness of effector cells, we analyzed the interactions between these cells and type I IFN DC. DC were generated from monocytes in the presence of IFN-beta and interleukin (IL)-3 (DCI3) or granulocyte macrophage-colony-stimulating factor and IL-4 (DCG4) and activated by poly(I:C). Despite the release of lower amounts of IL-12 after maturation, DCI3 were able to induce a higher IFN-gamma production by T lymphocytes during the mixed leucocyte reaction (MLR) as compared with DCG4. mRNA analysis disclosed that DCI3 overtranscribed the IL-6 gene and secreted high amounts of the protein. Neutralization of IL-6 revealed that this cytokine specifically contributed to the IFN-gamma release induced by DCI3. Finally, depletion of CD25+ T cells before the MLR identified these cells as a target for IL-6. We conclude that DCI3 are endowed with the property of regulating the suppressive effect of regulatory T cells through high IL-6 production. This novel mechanism of T cell control is relevant for the use of DCI3 in vaccination strategies.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15935883     DOI: 10.1016/j.humimm.2005.01.012

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  13 in total

Review 1.  Immunological decision-making: how does the immune system decide to mount a helper T-cell response?

Authors:  Gerard E Kaiko; Jay C Horvat; Kenneth W Beagley; Philip M Hansbro
Journal:  Immunology       Date:  2007-11-05       Impact factor: 7.397

2.  Linkage between Toll-like receptor (TLR) 2 promotor and intron polymorphisms: functional effects and relevance to sarcoidosis.

Authors:  M Veltkamp; P A H M Wijnen; C H M van Moorsel; G T Rijkers; H J T Ruven; M Heron; O Bekers; A M E Claessen; M Drent; J M M van den Bosch; J C Grutters
Journal:  Clin Exp Immunol       Date:  2007-06-12       Impact factor: 4.330

3.  Potentiating functional antigen-specific CD8⁺ T cell immunity by a novel PD1 isoform-based fusion DNA vaccine.

Authors:  Jingying Zhou; Allen Kl Cheung; Henggui Liu; Zhiwu Tan; Xian Tang; Yuanxi Kang; Yanhua Du; Haibo Wang; Li Liu; Zhiwei Chen
Journal:  Mol Ther       Date:  2013-04-16       Impact factor: 11.454

4.  The perioperative effect of anesthetic drugs on the immune response in total intravenous anesthesia in patients undergoing minimally invasive gynecological surgery.

Authors:  Marius Bogdan Novac; Lidia Boldeanu; Luciana Teodora Rotaru; Anda Lorena Dijmărescu; Mircea Sebastian Şerbănescu; Lucreţiu Radu; Simona Daniela Neamţu; Alina Maria Vîlcea; Mihaela Niculescu; Cecil Sorin Mirea; Mihail Virgil Boldeanu; Maria Magdalena Manolea
Journal:  Rom J Morphol Embryol       Date:  2021 Oct-Dec       Impact factor: 0.833

Review 5.  Oncolytic viruses: a novel form of immunotherapy.

Authors:  Robin J Prestwich; Kevin J Harrington; Hardev S Pandha; Richard G Vile; Alan A Melcher; Fiona Errington
Journal:  Expert Rev Anticancer Ther       Date:  2008-10       Impact factor: 4.512

6.  Inflammatory tumour cell killing by oncolytic reovirus for the treatment of melanoma.

Authors:  F Errington; C L White; K R Twigger; A Rose; K Scott; L Steele; L J Ilett; R Prestwich; H S Pandha; M Coffey; P Selby; R Vile; K J Harrington; A A Melcher
Journal:  Gene Ther       Date:  2008-04-10       Impact factor: 5.250

7.  Unique gene expression profiles in infants vaccinated with different strains of Mycobacterium bovis bacille Calmette-Guerin.

Authors:  Bo Wu; Chunhong Huang; Lourdes Garcia; Alfredo Ponce de Leon; Jose Sifuentes Osornio; Miriam Bobadilla-del-Valle; Leticia Ferreira; Sergio Canizales; Peter Small; Midori Kato-Maeda; Alan M Krensky; Carol Clayberger
Journal:  Infect Immun       Date:  2007-05-14       Impact factor: 3.441

8.  Immune activation by combination human lymphokine-activated killer and dendritic cell therapy.

Authors:  E J West; K J Scott; V A Jennings; A A Melcher
Journal:  Br J Cancer       Date:  2011-08-16       Impact factor: 7.640

9.  Interleukin-6 signaling drives fibrosis in unresolved inflammation.

Authors:  Ceri A Fielding; Gareth W Jones; Rachel M McLoughlin; Louise McLeod; Victoria J Hammond; Javier Uceda; Anwen S Williams; Mark Lambie; Thomas L Foster; Chia-Te Liao; Christopher M Rice; Claire J Greenhill; Chantal S Colmont; Emily Hams; Barbara Coles; Ann Kift-Morgan; Zarabeth Newton; Katherine J Craig; John D Williams; Geraint T Williams; Simon J Davies; Ian R Humphreys; Valerie B O'Donnell; Philip R Taylor; Brendan J Jenkins; Nicholas Topley; Simon A Jones
Journal:  Immunity       Date:  2014-01-09       Impact factor: 31.745

Review 10.  Type I interferons as regulators of human antigen presenting cell functions.

Authors:  Sandra Gessani; Lucia Conti; Manuela Del Cornò; Filippo Belardelli
Journal:  Toxins (Basel)       Date:  2014-05-26       Impact factor: 4.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.